Intel stock spikes after report of possible US government stake
LOS ANGELES - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company with a market capitalization of $12.6 million, has announced the completion of the safety lead-in phase of its Phase 2 clinical trial for ENV105, a treatment for metastatic, castration-resistant prostate cancer. This initial stage combined apalutamide, an established prostate cancer therapy, with Kairos’s own compound ENV105. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet, positioning it well for continued clinical development.
Following the safety assessment, the study has now progressed to the randomized phase, where patients will receive either apalutamide alone or in combination with ENV105. The company anticipates releasing safety and efficacy data from the safety arm of the trial starting in the first half of 2025. Trading at $0.92 per share, KAPA stock has experienced significant volatility, with InvestingPro analysis indicating the stock is currently undervalued based on its Fair Value assessment. Investors can explore similar opportunities through the Most Undervalued Stocks list.
Dr. John Yu, CEO of Kairos Pharma, expressed satisfaction with the trial’s progress and gratitude towards the participating medical centers for their commitment. Kairos continues to enroll patients for the randomized segment of the trial at leading cancer centers in Los Angeles and Salt Lake City.
The trial is not only backed by Kairos Pharma but also supported by a grant from the National Cancer Institute (NCI). An additional focus of the study is the validation of biomarkers, which may help identify patients most likely to benefit from the combination therapy.
Kairos Pharma specializes in oncology therapeutics, leveraging structural biology to tackle drug resistance and immune suppression in cancer. Their lead candidate, ENV105, is an antibody that targets CD105, a protein linked with resistance to various cancer treatments. The goal of ENV105 is to counteract drug resistance by inhibiting CD105, thereby enhancing the efficacy of standard therapies across multiple cancer types. ENV105 is also undergoing a Phase 1 trial for lung cancer.
This press release includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These statements are based on current expectations and projections about future events. Notably, InvestingPro analysis reveals that analysts do not expect profitability this year, with the company maintaining a current ratio of 2.84, indicating strong short-term liquidity. InvestingPro subscribers have access to over 30 additional financial metrics and insights for KAPA, along with real-time alerts and expert analysis.
The information provided in this article is based on a press release statement from Kairos Pharma, Ltd.
In other recent news, Kairos Pharma has reported a significant advancement in the treatment of non-small cell lung cancer (NSCLC). Their research identifies a mechanism to overcome resistance to EGFR-targeted therapies using ENV105, a CD105-neutralizing antibody. This promising development is currently undergoing clinical trials, highlighting the potential of ENV105 to enhance the effectiveness of existing cancer treatments. Additionally, Kairos Pharma presented positive preclinical data on their KROS platform at a recent cancer research conference, showcasing compounds KROS 101 and KROS 401, which demonstrated potential in treating melanoma and glioblastoma. The company also secured $3.5 million through a private investment in public equity (PIPE) transaction, further supporting their clinical trials and development projects. In 2024, Kairos Pharma achieved key milestones, including the addition of City of Hope Cancer Center to their Phase 2 trial of ENV105 for prostate cancer. Looking ahead, the company plans to continue trials for ENV105 in prostate and lung cancers, with initial safety data expected in 2025. These developments reflect Kairos Pharma’s ongoing efforts to advance its oncology therapeutics portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.